JP2009539845A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539845A5
JP2009539845A5 JP2009514365A JP2009514365A JP2009539845A5 JP 2009539845 A5 JP2009539845 A5 JP 2009539845A5 JP 2009514365 A JP2009514365 A JP 2009514365A JP 2009514365 A JP2009514365 A JP 2009514365A JP 2009539845 A5 JP2009539845 A5 JP 2009539845A5
Authority
JP
Japan
Prior art keywords
cmv
pul128
pul130
protein
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009514365A
Other languages
English (en)
Japanese (ja)
Other versions
JP5822433B2 (ja
JP2009539845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/013365 external-priority patent/WO2007146024A2/en
Publication of JP2009539845A publication Critical patent/JP2009539845A/ja
Publication of JP2009539845A5 publication Critical patent/JP2009539845A5/ja
Application granted granted Critical
Publication of JP5822433B2 publication Critical patent/JP5822433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009514365A 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 Active JP5822433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20
PCT/US2007/013365 WO2007146024A2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013154361A Division JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Publications (3)

Publication Number Publication Date
JP2009539845A JP2009539845A (ja) 2009-11-19
JP2009539845A5 true JP2009539845A5 (https=) 2010-06-17
JP5822433B2 JP5822433B2 (ja) 2015-11-24

Family

ID=38832360

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Country Status (5)

Country Link
US (5) US7704510B2 (https=)
EP (2) EP3031469B1 (https=)
JP (3) JP5822433B2 (https=)
CA (1) CA2654563A1 (https=)
WO (1) WO2007146024A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
CA2682700A1 (en) * 2007-05-11 2008-11-20 Vakzine Projekt Management Gmbh Composition containing hcmv particles
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AU2013202396B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
PE20141435A1 (es) 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2303923B1 (en) * 2008-07-16 2015-06-24 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) * 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
WO2011076883A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
US20130164289A1 (en) * 2010-09-09 2013-06-27 Virginia Commonwealth University Human cytomegalovirus vaccine
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
KR20140138971A (ko) * 2012-03-28 2014-12-04 제넨테크, 인크. 항-hcmv 이디오타입 항체 및 이들의 용도
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US20150322115A1 (en) * 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
KR20250006307A (ko) * 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
CN112512569A (zh) 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
KR102837045B1 (ko) 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US20230293673A1 (en) * 2020-08-06 2023-09-21 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
AU2002247733B2 (en) * 2001-02-21 2007-12-13 The Wistar Institute Of Anatomy And Biology Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
DE10232322A1 (de) * 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Similar Documents

Publication Publication Date Title
JP2009539845A5 (https=)
US11129891B2 (en) Cytomegalovirus surface protein complex for use in vaccines and as a drug target
CA2809780C (en) Influenza virus neutralizing antibody and method for screening same
CA3081694C (en) Monoclonal antibodies for ebola and marburg viruses
JP2013241442A5 (https=)
Thornlow et al. Altering the immunogenicity of hemagglutinin immunogens by hyperglycosylation and disulfide stabilization
CN110294802B (zh) 一种单克隆抗体10g12及其应用
CN114478755A (zh) 抗新型冠状病毒的全人源抗体及其组合物与应用
TW202144405A (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
Wang et al. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA. 1-BA. 5
Stryjewska et al. Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy
WO2011137571A1 (zh) 人源抗狂犬病毒糖蛋白中和性抗体rvfab5
CN104220090A (zh) 肠道病毒71型的特异性抗体及其用途
CN105985433B (zh) 针对h7n9亚型禽流感病毒的全人源单克隆抗体及应用
de Carvalho Nicacio et al. Neutralizing human Fab fragments against measles virus recovered by phage display
CN114805570B (zh) 一种抗人ace2单克隆抗体及其应用
CN105481979A (zh) 人源抗狂犬病毒糖蛋白中和性抗体rv3a5及其应用
Liu et al. Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine
CN109212205B (zh) 伪狂犬病病毒gC蛋白抗体、含该抗体的试剂盒及应用
Zhang et al. A recombinant avian antibody against VP2 of infectious bursal disease virus protects chicken from viral infection
Pastrana et al. Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid
CN117777280A (zh) 新型冠状病毒SARS-CoV-2广谱中和单域抗体及其应用
Gillet et al. Glycoprotein L sets the neutralization profile of murid herpesvirus 4
CN113583118A (zh) 用于检测番鸭呼肠孤病毒的单链抗体、嵌合抗体和双夹心elisa检测试剂盒
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途